Recent Studies on Safety of PDE-5 Inhibitors with Antihypertensive Medicines and Nitrates: Should Nitrates Remain a Contraindication or Now Be Considered a Warning?

Login

Password

Forgot your password?

Join VuMedi

Select specialty

First name

Last name

Choose Password

About Us
Careers
Partner with us
F.A.Q
Contact us
Terms & conditions
Privacy policy

Playback speed

10 seconds

Recent Studies on Safety of PDE-5 Inhibitors with Antihypertensive Medicines and Nitrates: Should Nitrates Remain a Contraindication or Now Be Considered a Warning?

By "Princeton 4: PDE5 Inhibitors and Cardiac Health Symposium.” Huntington Medical Research Institutes, Pasadena, CA. Friday, March 10th, 2023. FEATURING Peter Ganz

134 views

July 11, 2023

Speaker Name and Title: Peter Ganz MD
The Princeton 4 meeting was sponsored by an ...
read more ↘ unrestricted grant from Sanofi.
Sanofi was not involved in choosing the content or speakers for the meeting.

Affiliation of the speaker:
Zuckerberg San Francisco General Hospital and University of California, San Francisco

Title of the speaker’s talk: “Recent studies on safety of PDE-5 inhibitors with antihypertensive medicines and nitrates. Should nitrates remain a contraindication or now be considered a warning?”

Financial disclosure/Conflict of Interest:
- Dr. Ganz serves on the medical advisory board of SomaLogic, a proteomics company, for which he accepts no financial remuneration of any kind.

- Dr. Ganz is a Scientific Advisor to Riparian Pharma, which is developing a pharmacological agent to reverse endothelial dysfunction.
↖ read less

Comments 0